The impact of long-acting progestin contraception on the vaginal microbiome by Doherty, Ann
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2021
The impact of long-acting progestin





SCHOOL OF MEDICINE 
Thesis 
THE IMPACT OF LONG-ACTING PROGESTIN CONTRACEPTION
ON THE VAGINAL MICROBIOME  
by 
ANN DOHERTY 
B.S., Northeastern University, 2016
Submitted in partial fulfillment of the 
requirements for the degree of 
Master of Science 
2021 
© 2021 by 
ANN DOHERTY 
All rights reserved 
Approved by 
First Reader 
Wendy Kuohung, M.D. 
Associate Professor of Obstetrics and Gynecology 
Second Reader 
Doyle V. Ward, Ph.D. 
Associate Professor of Microbiology and Physiological Systems 





I would like to thank all of the participants who enrolled in this study, Dr. Doyle Ward 
for his expertise and assistance in analyzing the dataset, and my mentor and supervisor, 





THE IMPACT OF LONG-ACTING PROGESTIN CONTRACEPTION  
ON THE VAGINAL MICROBIOME  
ANN DOHERTY 
ABSTRACT 
 Progestins are synthetic progestogens that prevent pregnancy by thickening the 
mucous of the cervix to prevent sperm entry and by disrupting implantation via alteration 
of the timing of endometrial changes occurring during a normal menstrual cycle.  Various 
hormonal birth control methods utilize progestins, with some of the most effective types 
of birth control methods being long-acting reversible contraceptives.  These include 
hormonal injections such as depot medroxyprogesterone acetate (DMPA), hormonal 
implants such as Nexplanon, and hormone-releasing intrauterine devices (IUDs) such as 
Mirena.  Although there have been many studies on the safety and effectiveness of these 
methods, fewer studies have examined how these hormonal methods may impact the 
bacterial environment of the vagina, better known as the vaginal microbiome. The health 
of the vagina relies heavily on the bacteria composing the microbiome.  Changes in 
species composition correlate with higher risk of sexually transmitted infections (STIs) 
and adverse pregnancy outcomes.  When women select their preferred hormonal 
contraceptive method, they should know if it will impact their vaginal microbiome and 
increase susceptibility to disease. Twenty-one patients enrolled in this study, with one 
patient initiating DMPA, 14 initiating levonorgestrel (LNG) IUD, and 6 initiating the 
etonogestrel subdermal implant (ESI).  At initiation, 3 months post initiation, and 6 
months post initiation, no differences were seen in the vaginal microbiomes of each of 
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the women enrolled in the study.  Some differences in the vaginal microbiota of 
postpartum women and those who were not postpartum were seen.  More specifically, 
enrichment of three families, Lachnospiraceae, Ruminococcaceae, and 
Erysipelotrichaceae, was seen in women who were more than 12 weeks postpartum, but 
the effects of those differences remain unclear. Although our sample size was small, the 
lack of changes in the vaginal microbiome in women initiating long-acting progestin 
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Overview of Modern Contraception 
 There are many options available today in both hormonal, barrier, and behavioral 
birth control methods.  Some of these methods are reversible and some are not.  Overall, 
hormonal birth control methods are the most popular and widely used methods in the 
United States (Blumenthal, 2008). 
 Hormonal contraception may vary widely in terms of its effectiveness and 
delivery method.  All forms of hormonal contraception include a progestogen, and many 
forms also include some type of estrogen for improved period control.  Over the years, 
the dosage of estrogen has been reduced to curb unwanted side effects such as nausea, 
headache, weight gain, and episodes of venous thromboembolism.  Today’s combination 
contraceptives contain one of two forms of estrogen, ethinyl estradiol or estradiol.  By 
including synthetic estrogen in these combination options, the levels of estrogen within 
the body remain more consistent, preventing a rise in follicle-stimulating hormone, the 
recruitment of a dominant follicle, and hence ovulation.  The primary reason for 
including estrogen in combined hormonal contraception is to help regulate bleeding so it 
occurs at more predictable intervals (Blumenthal, 2008). 
 There are many different synthetic progestogens or progestins currently in use in 
various types of hormonal contraceptives today.   The contraceptive effect of progestin 
occurs due to three mechanisms of action.  Progestins have an antigonadotrophic effect 
that inhibits ovulation specifically by blocking the LH surge, although this does not 
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happen consistently at lower doses.  Progestin contraception also relies on effects on the 
endometrium and cervical mucus.  Progestins thicken the cervical mucus, thereby 
preventing sperm entry.  They also disrupt implantation by altering the timing of 
endometrial changes occurring during a normal menstrual cycle, leading to thinning and 
atrophy of the endometrium (Regidor, 2018). 
 In addition to their contraceptive effects, combination contraceptives also offer 
other advantages, specifically due to their progestin component.  These contraceptives 
offer some protection against certain types of endometrial and ovarian cancers, decrease 
menstrual flow, help with dysmenorrhea, and may lessen the negative effects of 
endometriosis.  Additionally, combined contraceptive methods can often improve acne 
and reduce unwanted hair growth due to increases in sex hormone binding globulin that 
binds androgen.  Combined contraceptives may also reduce menstrual migraine 
frequency and painful cramps associated with the menstrual cycle (Regidor, 2018). 
 There are some progestin-only forms of contraception that are ideal for women 
that cannot take estrogen due to other health issues or who are especially sensitive to side 
effects of estrogen-containing contraception.  Women who benefit from progestin-only 
pills include those who smoke, have high blood pressure, are overweight, are nursing, or 
have a history of blood clots.  There are many contraindications to using combination 
hormonal pills including metabolic and cardiovascular side effects.  High doses of 
combined hormonal contraception have been associated with an increased incidence of 
glucose intolerance and with an increased risk of venous thromboembolism (deep vein 
thrombosis, stroke, and myocardial infarction (Regidor, 2018).  As the amount of 
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estrogen in these contraceptives decreases, so do the adverse effects.  Typically, when 
estrogens are formulated with newer progestins, the risk of adverse side effects also 
increases (De Leo, 2016).  Some of these risks increase with both age, smoking, and 
weight.   The higher the dose of estrogen in the pills, the more likely minor side effects 




Figure 1: Overview of Modern Contraception.  Effectiveness of various family 
planning methods from the Family Planning Global Handbook for Providers. (Festin, 
2020) 
 
 Permanent birth control methods include sterilization of males or females.  In 
women, sterilization may be achieved via tubal ligation, a surgical procedure that blocks 
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or cuts the fallopian tubes, preventing the sperm from encountering the egg.  In men, a 
vasectomy is permanent birth control.  In this procedure, shorter and less invasive than a 
tubal ligation, the vasa deferentia are blocked or cut, preventing sperm from entering the 
ejaculatory fluid.  When looking at worldwide utilization of tubal ligations and 
vasectomies, nearly 20% of reproductive-aged women have undergone sterilization 
compared to only 3% of men (Festin, 2020). 
 After sterilization, the next most effective form of birth control is long-acting 
reversible contraceptive methods (LARCs).  These include hormonal contraceptive 
implants and intrauterine devices (IUDs).  IUDs consist of small plastic or metal devices 
in different shapes that may be inserted through the cervix and maintain their position in 
the triangular uterine cavity.  The most commonly used IUDs in the United States are T-
shaped devices These IUDs prevent pregnancy either by releasing progestin or by using 
copper.  ParaGard® is a copper IUD that is nonhormonal and can provide contraception 
for up to 12 years.  The copper is toxic to sperm, damaging sperm so they cannot swim to 
meet the egg.  The copper IUD is advantageous for women trying to avoid hormonal 
methods of birth control.  Additionally, the copper IUD can be used as emergency 
contraception if it is inserted within 120 hours after unprotected sex. Adverse effects of 
the copper IUD include painful periods and heavier menstrual bleeding.  Just over 1 in 10 
women who have a copper IUD placed will have it removed within the first year of use 
due to heavier bleeding and cramping (Hsia, 2016). 
 There are several hormonal IUDs available in the United States.  They all contain 
progestin that prevents the sperm from meeting the egg by thickening the cervical mucus.  
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Each hormonal IUD differs slightly in duration of contraceptive protection, but they 
range from 3 to 7 years.  The design is similar to a copper IUD except that the T-arms 
fold upwards instead of downwards during insertion.  The most popular IUD in the 
United States is the Mirena® IUD.  This IUD releases 20ug of levonorgestrel daily for 
the first few weeks.  One year after insertion, the amount decreases to 18ug per day, and 
after 5 years, there is roughly 10ug per day released.  Liletta® is a similar product to 
Mirena and is also commercially available in the United States.  A smaller 
levonorgestrel-releasing IUD, Skyla®, is approved for 3 years of use and is available on 
the US market.  IUDs are advantageous because once they are in place, there is nothing 
the user has to think about with regards to contraception other than protecting herself 
from sexually transmitted infections.  Aside from their success as contraceptives, 
progestin IUDs can also help users with heavy menstrual bleeding and cramping and are 
considered a great nonsurgical and affordable option for users with anemia or irregular 
uterine bleeding (Hsia, 2016).   
 The most effective hormonal contraceptives are implants containing 
levonorgestrel or etonorgestrel.  These devices, along with IUDs, are long-term 
contraceptive methods that slowly release hormones over a period of 3-5 years.  Implants 
are subcutaneous devices that are typically implanted in the upper arm of the user.  All 
implants prolong the action of a short-acting hormone, typically a progestin, by releasing 
a continuous amount of drug from a reservoir within the implant itself.  Implants usually 
come as rods that have polymers mixed with steroid or as capsules filled with steroid 
crystals. One major obstacle in the way of more women utilizing implants as their choice 
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of contraception is the need for the provider to have specific training in order to implant 
and remove it safely (Benagiano, 2015). 
 Today, there are two main implants available worldwide.  The Norplant-2® 
contains two rods filled with a polymer-levonorgestrel matrix.  There is 140mg of active 
hormone contained in the rods, and it can continuously and effectively release hormone 
for up to five years.  Implanon® is another implant option containing a single rod with 
68mg of etonogestrel.  This implant is effective for four years based on recent studies that 
show high serum etonogestrel levels through 48 months.  Ovulation often resumes prior 
to year 3-4, but the thickened cervical mucus and endometrial dysregulation continue to 
prevent pregnancy.  A newer version of Implanon is Nexplanon®.  It is approved for 3 
years and contains barium sulfate that helps locate it on X-ray.  Nexplanon is more easily 
inserted and removed than Implanon.  Within the last few years, removal was made easier 
by using ultrasound to mark the surface.  With etonogestrel implants, 20% of users have 
it removed due to irregular bleeding before it is no longer effective (Benagiano, 2015).  
 Shorter acting hormonal contraceptives come in an oral (combination) pill form, 
injections, transdermal patches, and vaginal rings.  Pills can be monophasic, biphasic, or 
triphasic.  In monophasic pills, the active pills contain a constant dose of hormones, 
whereas in diphasic and triphasic formulations, the hormone dose increases once or 
twice, respectively, during the cycle.  The diphasic and triphasic contraceptives are meant 
to mimic the normal physiology of the menstrual cycle, but there is  no evidence that 
these formulations offer advantages to monophasic formulations (De Leo, 2016).   
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 Combination pills can be taken different ways.  Some pills are 21/7 or 24/4, where 
21 days or 24 days are active hormone-containing pills and 7 or 4 pills are placebos, with 
the 24/4 having the advantage of a shorter placebo interval.  There are also 21 or 28-day 
pill packs that contain only active pills and are meant to be taken back-to-back with no 
breaks in between.  Women on these formulations will not have a period (De Leo, 2016).  
Lastly, there are 91-day pill packs designed for women who only want a period 4 times a 
year, so 84 days will be hormonal pills and the last 7 days will be placebo pills (Davis, 
2010).  There is also a progestogen-only pill (minipill) that is safer for women who are 
breastfeeding or who have elevated cardiovascular risks (Regidor, 2018).  The risk of 
breakthrough bleeding with the progestin-only pill is higher as the stabilizing effect of 
estrogen on the endometrium is lacking. 
 Injectable contraceptives are usually combination or progestin-only formulations.  
The two main types of progestin-only contraceptives are depot medroxyprogesterone 
acetate (DMPA) or norethisterone enanthate (NET-EN).  DMPA can be injected intra-
muscularly (IM) in a 150-mg dose or subcutaneously (SC) in a 104-mg dose and is good 
for 3 months because it is slowly released into the bloodstream after injection.  
Subcutaneous injections of DMPA are more easily performed by the patient.  DMPA, 
similar to typical hormonal methods containing progestin, has a three-pronged effect in 
preventing pregnancy:  it inhibits ovulation, thickens the cervical mucus, and thins the 
lining of the endometrium.  When utilizing DMPA, normal fertility takes longer to return, 
with an average of 5-8 menstrual cycles (Yland, 2020).  DMPA is safe and effective 
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immediately after an abortion, immediately postpartum if the user is not breast feeding, 
or 6 weeks postpartum in users who are breast feeding (Blumenthal, 2008). 
 Those who are pregnant or have breast cancer should not use DMPA.  The most 
common side effect with DMPA is irregular bleeding, which is also the main reason that 
women opt for alternative contraceptive options.  DMPA also has some noncontraceptive 
benefits including a reduction in endometrial carcinoma. DMPA users often see a 
reduction in anemia and ovarian cysts as well.  Other effects of DMPA include stabilizing 
the erythrocyte membrane and increasing the hematocrit (by decreasing blood loss) in 
users with sickle cell anemia, increasing the seizure threshold in users with epilepsy, and 
protecting users at higher risk factor for pelvic inflammatory disease (PID) by decreasing 
the risk of infections by thickening the cervical mucus.  There are some risks associated 
with DMPA, including weight gain and reversible decreases in bone density, especially in 
younger women.  Patients who are heavy smokers, elite athletes with amenorrhea, or 
steroid users, as well as patients with anorexia nervosa, should find alternative methods 
due to their increased risk of bone density loss (Blumenthal, 2008).  
 NET-EN, the other main type of progestin-only injectable, needs to be given 
every 2 months and is also injected either IM or SC.  NET-EN prevents ovulation and 
upon stopping, fertility will return in 3 to 4 months on average.  Although not currently 
available in the U.S., there are many combination injectables available.  These 
formulations may include either medroxyprogesterone acetate with estradiol cypionate or 
NET-EN with estradiol valerate.  Unlike progestin-only options, these need to be injected 
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monthly and it takes slightly longer, on average 5 months, for fertility to return after 
method discontinuation (Festin, 2020). 
 The contraceptive patch contains a combination of progestin and estradiol.  The 
patch is slightly smaller than a 2x2-inch square that is placed on the upper outer arm, 
buttocks, abdomen, or upper torso.  Hormones are released into the skin, where they are 
absorbed into the bloodstream.  The patch is changed weekly for three weeks.  The fourth 
patch-free week is when the user’s period should begin.  Each week, the patch may be 
rotated to a different location in order to avoid irritation.  Like combination pills, the 
patch may increase the risk of blood clots, especially in users over 35 years of age who 
smoke.  The patch may be less effective in users over 200 pounds (Benagiano, 2006).   
 Vaginal rings offer another type of combination hormonal contraceptive.  These 
rings are inserted into the vagina, where they release a continuous level of hormones into 
the bloodstream via the vaginal epithelium.  Currently, there are two rings available on 
the market, the NuvaRing® and Annovera®.  NuvaRing has been available for over two 
decades; it releases 15 mg of ethinyl estradiol and 120 mg of etonogestrel and is changed 
monthly (Benagiano, 2006).  The ring should be inserted for 21 days followed by 7 days 
where the ring is removed to induce a period (Lee, 2020).  The Annovera contains 17.4 
mg of ethinyl estradiol and 103 mg of segesterone acetate and contains enough hormone 
to last for one year.   
 The expulsion rate of Annovera is higher than the NuvaRing, with about 25% of 
women reporting a complete expulsion at least one time during their year of use.  
Adverse effects of both rings are similar to the effects seen with other combination 
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hormonal contraceptives including dysmenorrhea, vaginal discharge, irregular bleeding, 
headache, nausea, and breast tenderness.  About 12-15% of users will discontinue use due 
to these adverse effects.  The effectiveness of contraceptive rings is similar to other 
hormonal contraceptives, with about 1-3 pregnancies per 100 women each year (Lee, 
2020).   
 There are also barrier methods used by the female that are slightly-less effective 
forms of birth control, including diaphragms, sponges, cervical caps, spermicides, and 
female condoms.  The male and female condoms are the best protection against STIs.  
The major benefit of barrier methods is that they are safe for women who have a 
contraindication to hormonal methods.  Diaphragms are circular and made of silicone.  
They are filled with spermicidal jelly and inserted into the vagina before intercourse, and 
they cover the cervix, preventing sperm from being able to enter the uterus to fertilize the 
egg.  They should be left in the vagina for 6 hours after intercourse but no longer than 24 
hours post intercourse.  There is a “one-size-fits-all” diaphragm that does not require 
fitting by a physician, the Caya® diaphragm, now available on the market.  Currently, the 
Today Sponge is the only sponge approved for use in the United States.  The sponge is 
circular, made of polyurethane foam, and contains a spermicide.  It is inserted before 
intercourse and removed 6 or more hours after intercourse.  The Today Sponge may be 
washed in between uses for re-use.  The efficacy rate for the Today Sponge, when used 
correctly, is between 84% and 87% (Tracy, 2017). 
 Cervical caps are similar to diaphragms.   There is only one commercially 
available cervical cap on the market in the United States, the FemCap.  It is made of 
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silicone and circular in shape.  Similar to most diaphragms, a prescription is needed for a 
cervical cap, and it needs to be properly sized by a clinician.  There are a few sizes 
available: a 22 mm, generally for women who have never been pregnant; 26 mm, for 
anyone who has been pregnant for any period of time, and 30 mm for women who have 
given birth via vaginal delivery.  It is often recommended to use a spermicide with the 
cervical cap.  Success rates of the cervical cap range from 71% to 86%.  The FemCap 
should be left in the vagina for at least 6 hours after intercourse, but not longer than 2 
days. 
 A commercially available spermicide in the United States is Noxonyl-9.  It is 
available as a film, gel, foam, cream, or suppository.  Its recommended use is with a 
diaphragm or cervical cap, but it can be used alone if it is placed in the vagina at least 10 
minutes before intercourse.  Spermicides work by chemically immobilizing sperm 
(Tracy, 2017).   
 Both female and male condoms are available without a prescription.  Female 
condoms are 75- 92% effective at preventing pregnancy and also protect against STIs.  
Female condoms are larger than male condoms and contain two rings.  Typically, they 
are made of nitrile or polyurethane.  The ring at the closed end is inserted into the vagina 
to cover the cervix.  The other ring on the open side of the condom sits on the outside of 
the vulva.  Male condoms are a popular choice of contraception, especially among 
younger adults, that also offering protection against STIs.   The male condom, like the 
female condom, is single use and should be used consistently when relying solely on it 
for contraceptive purposes.  The male condom should be placed on the penis after it 
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becomes erect, avoiding trapping air in the tip.  Water-based lubricants should always be 
used with latex condoms to avoid weakening them.   Male condoms, when used correctly, 
are 82% effective at preventing pregnancy (Tracy, 2017).   
 Lastly, there are also behavioral contraceptive methods available for couples. 
Most of the behavioral contraceptive methods are referred to as fertility awareness-based 
methods (FABMs).  FABMs rely on day-to-day female physiological data to determine 
fertile periods.  Based on whether she is fertile or not, a woman utilizing FABMs may 
abstain from sex or use a barrier method such as a condom, diaphragm, sponge, 
spermicide or cervical cap.  On days when she is not fertile, intercourse can proceed 
without any forms of contraception.  Couples who are trying to get pregnant would utilize 
the fertile days to increase their chances of conceiving.  Some couples not wanting to 
conceive are completely abstinent during fertile days because their beliefs do not support 
the use of contraception.  This is referred to as the Natural Family Planning Method 
(Simmons, 2020).  Another relatively popular behavioral method is coitus interruptus or 
the withdrawal method, where the male removes his penis from the vagina prior to 
ejaculation.  Although the withdrawal method has advantages such as its lack of cost and 
its total access, it is one of the least effective methods of contraception, with 1 in 5 
women getting pregnant using this method alone (Nguyen, 2020).   
 
Common Sexually Transmitted Infections 
 Most methods of birth control can prevent pregnancy but cannot protect against 
sexually transmitted infections (STIs).   The only birth control methods that can protect 
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against both unwanted pregnancies and transmission of STIs are (external) male condoms 
and (internal) female condoms.  STIs can be transmitted by bacteria, viruses, or other 
types of pathogens.  Common bacterial STIs include syphilis, gonorrhea, and chlamydia.  
Syphilis is caused by Treponema (T.) pallidum.  Each year, there are approximately 6 
million new syphilis infections around the world, with more infections occurring in men 
having sexual intercourse with men.  Syphilis is transmitted orally, anally, or through 
genital contact.  Normally, a sore, or chancre, will appear at the infection site three weeks 
after contact with an infected partner.  At this point, antibodies to the bacteria can be 
detected.  There are four stages of syphilis infection, including the latent asymptomatic 
third phase.  All four stages can be treated with penicillin.  Untreated syphilis may result 
in death, or it can resolve by itself after the second stage (Buder, 2019).   
 Gonorrhea is transmitted by Neisseria gonorrhoeae during sexual intercourse or 
childbirth.  Each year there are just over 70 million cases of gonorrhea reported 
worldwide.  Unfortunately, about half of those who are infected do not realize it because 
they are asymptomatic, and will transmit the infection even without symptoms.  When 
gonorrhea does present with symptoms, typically they occur 1-14 days after transmission 
and affect the mucous membranes at and around the site of infection.  In women, the 
cervical canal is most commonly infected, accompanied by symptoms such as vaginal 
discharge and painful urination.  In men, there can be some discharge from the urethra 2-
6 days after infection, accompanied by painful urination.  The only effective antibiotic for 
treating gonorrhea infections is ceftriaxone, and the threat of an untreatable or multi-drug 
resistant strain of N. gonorrhoeae surfacing in the near future is real (Fuchs, 2014).   
 
14 
 Chlamydia is caused by Chlamydia trachomatis which has two biovars, the 
trachoma biovar that causes urogenital infections and is one of the top three most 
common causes of STIs worldwide, and the lymphogranuloma venereum biovar that is 
much more invasive, causing systemic spread via the lymphatic system upon infection.  
Chlamydia usually presents as an infection of the respiratory tract or urogenital tract, but 
it can also infect the conjunctivae.  Many infections in both men and women are largely 
asymptomatic, so many chlamydial infections go undiagnosed and may lead to infertility 
in both men and women.  Undiagnosed infections can cause reactive arthritis 1-2 months 
after exposure.  Some men experience inflammation of the urethra after exposure, leading 
to discharge and painful urination.  Very few women experience symptoms that may 
include pelvic pain, discharge, and bleeding from cervical infection.  Urogenital 
chlamydial infection is treated with doxycycline or azithromycin, depending upon patient 
circumstances/adherence (Buder, 2019). 
 Trichomonas infection is a parasitic infection caused by Trichomonas vaginalis 
that can also be treated with antibiotics.  Often, those who are infected are asymptomatic 
as with many bacterial STIs.  The few men who have symptoms will present with 
inflammation of the urethra, epididymis, or prostate.  When women have symptoms, they 
present with vaginal discharge. Those infected with trichomonas, as is the case with 
many other STIs, are at an elevated risk of contracting other STIs, especially human 
immunodeficiency virus (HIV).  When asymptomatic, trichomonas infection can last for 
a few months up to a few years.  This STI is treated with either metronidazole or 
tinidazole (Wagenlehner, 2016).   
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 There are several common viral STIs including human papillomavirus (HPV), 
human immunodeficiency virus (HIV), and herpes simplex virus (HSV).  Human 
papillomavirus consists of over 100 strains and is spread by skin-to-skin contact.  Certain 
strains are more high-risk for development of cancer than others.  HPV types 6 and 11 are 
known to cause genital warts (condyloma acuminata).  These are lower-risk strains that 
can be treated at the site of the wart with cryotherapy, trichloroacetic acid, or ablative 
techniques such as laser therapy.  When local treatment does not work, topical antimitotic 
creams such as podophyllotoxin, low doses of chemotherapy agents such as 5-fluoruracil, 
or immunosuppressants such as cyclosporine can be used to treat the genital warts.  High-
risk HPV types include 16 and 18.  These strains can cause malignant growths.  Nearly 
100% of cervical cancers are HPV positive, while 90% of anal cancers demonstrate HPV.  
HPV also causes 70% of carcinomas seen in the penis, vulva, and vagina, and 30% of 
carcinomas of the throat and tonsils.  There is a multivalent HPV vaccine available that is 
recommended to boys and girls ages 11-12 who have not yet had any form of sexual 
contact (Wagenlehner, 2016).  
 Human immunodeficiency virus, like herpes simplex virus, has the two strains 
HIV-1 and HIV-2, with HIV-1 (HIV) more commonly leading to end-stage acquired 
immunodeficiency syndrome (AIDS).  HIV is a retrovirus that infects cells by reverse 
transcribing its single-stranded ribonucleic acid (RNA) into deoxyribonucleic acid 
(DNA) before incorporating its viral genome into the host DNA, allowing the virus to 
continue replicating.  HIV is difficult to treat and to cure because the virus is excellent at 
overcoming the immune system of the host and the effects of the drugs used to treat it.  
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The virus eludes many mechanisms used to fight it through its characteristic variability, 
highlighting three odd features of HIV.  The three features that contribute to viral 
variation include the error prone enzymes that often introduce at least one genomic 
mutation each time the virus replicates, the rapid replication cycle that allows the virus to 
make many copies of itself each day, and the high likelihood of genetic recombination 
between two viral particles within the host.  HIV is spread to open skin regions via 
infected secretions or blood.  Without treatment, most people infected with HIV die from 
AIDS within 11 years of infection.  Although there is no cure for HIV or AIDS, 
antiretroviral therapy can slow the progression of HIV and limit complications due to 
secondary infections (Fanales-Belasio, 2010).  
 
 
Figure 2: Course of Human Immunodeficiency Virus.  During the asymptomatic 
phase, the virus is still replicating continuously while evading many immune 
mechanisms. As it is counteracting these mechanisms and replicating, the virus is 
creating a state of chronic inflammation that makes way for opportunistic infections, 




 There are two types of herpes simplex virus, HSV-1 and HSV-2.  Genital herpes 
infections are predominantly caused by HSV-2, which is transmitted via genital contact.  
HSV-1 is usually transmitted through oral secretions via oral-non-genital contact or oral-
genital contact.  Viral shedding and recurrence is much less common with genital HSV-1 
infections.  Infection with herpes virus can be silent, accounting for greater than 75% of 
viral transmission.  Typically, HSV-1 and 2 present similarly, with painful ulcers on the 
anus or genitalia being the hallmark of initial infection.  Often, those experiencing an 
initial infection also present with flu-like symptoms.  Episodes occurring after the initial 
infection are usually less severe, but in some cases the virus can cause severe disease and 
complications involving pneumonitis, systemic infection, meningitis, encephalitis, and 
hepatitis.  When HSV is symptomatic, patients should receive antiviral therapy 
immediately after their first episode.  Antivirals used to treat genital HSV infections 
include acyclovir, famciclovir, and valacyclovir (Siracusano, 2014).   
 
The Vaginal Microbiome  
 The human microbiota consists of various commensal and symbiotic 
microorganisms that live within and on the human body.  Microorganisms within our 
body’s microbiota include bacteria, archaea, protists, fungi, and viruses.  Bacteria can be 
classified according to how they produce energy.  Facultative anaerobic bacteria can 
generate energy in the form of adenosine triphosphate (ATP) either with or without 
oxygen, obligate anaerobic bacteria produce energy and survive in environments without 
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oxygen, and obligate aerobic bacteria produce energy and survive in environments with 
oxygen.  The genomes of these microorganisms are what compose the metagenome of the 
human body, and they have nearly 150 times more genes than the genome of humans.  
The major microbiome within the human body is the gut microbiome, but in women, the 
cervical and vaginal microbiota are believed to be of great importance in diseases and 
infections central to those regions.  Many diseases are believed to have some association 
with microbiotal disruption (Ata, 2019). 
 Within the vaginal microbiome, the interaction between the host and the 
organisms present is especially important.  Typically, the microbes in the vagina exist in 
a symbiotic relationship with their host.  The microorganisms found in the vaginal 
microbiome form the first line of defense against various pathogens that attempt to enter 
the body through the vagina.  The ecosystem of the vagina consists of an outer layer of 
stratified squamous epithelium and an inner mucosal layer lubricated with cervicovaginal 
fluid containing mucins, antimicrobial products, and antibodies.  The fluid of this mucus 
layer is largely responsible for maintaining the microbiota of the vagina (Torcia, 2019). 
 During a woman’s lifetime, the vaginal microbiome may go through vast changes.  
Puberty, pregnancy, and menopause all cause major changes in the vaginal microbiome, 
while daily choices may cause minor changes.  The vaginal microbiome is less diverse 
than the gut microbiome; typically, the more variation within the vagina, the worse the 
outcome in terms of disease and infection (Smith, 2017). 
 In women of reproductive age, it has been determined that there are five major 
community state types (CSTs), or vaginal microbial communities.  Four of the CSTs are 
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comprised of various types of lactic-acid producing Lactobacilli including L. crispatus 
(CST‐I), L. gasseri (CST‐II), L. iners (CST‐III), or L. jensenii (CST-V).  Although these 
are the main Lactobacilli species seen, over 20 types of lactobacilli have been detected in 
the vagina.  Typically, the fewer bacterial species composing the vaginal community, the 
healthier the vagina is likely to be (Huang, 2014). The 4th CST (CST-IV) lacks 
lactobacilli and is a mixture of anaerobes and strict anaerobes.  CST-IV has some species 
of the genera Gardnerella, Atopobium, Mobiluncus, Prevotella, as well as taxa from the 
Clostridiales order (Smith, 2017).   
The four CSTs that produce lactic acid are largely responsible for the acidic 
potential of hydrogen (pH) of the vagina, that is typically less than 4.5. The epithelial 
cells of the vagina produce glycogen that the Lactobacilli species feed on, fermenting it 
to produce D- and L-lactic acid.   Some of these Lactobacilli species also increase the 
production of mucus, the first line of immune defense of the vagina. The acidic 
environment is thought to prevent colonization of the vagina by unwanted pathogens 
(Smith, 2017).   
The Lactobacilli-dominant CSTs inhibit growth of non-native pathogens through 
the production of hydrogen peroxide and bacteriocins, which are peptides produced by 
bacterial strains that are toxic and lethal to bacterial strains that are closely related to the 
host bacteria (Smith, 2017).  Some researchers believe that the growth of non-native 
pathogens is predominantly due to the bacteriocins and not hydrogen peroxide because 
the Lactobacilli species can’t produce high enough levels of the hydrogen peroxide to 
actually inhibit growth, as seen in bacterial vaginosis (BV), a condition characterized by 
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an overgrowth of non-native bacteria in the vagina Lactic acid, however, can suppress the 
growth of bacteria causing BV (Huang, 2014).  Some of the bacteria seen in CST-IV such 
as Megasphera, Prevotella, Gardenella, and Sneathia are often associated with the 
presence of BV (Gupta, 2019).     
It is also believed that some species of Lactobacilli found in the vaginal 
microbiome keep non-native pathogens from colonizing because they outcompete these 
pathogens for nutrients and host cell surface receptors. Common non-native pathogens 
(some of which cause STIs and bacterial vaginosis) that are often out-competed by the 
native Lactobacilli include Gardnerella vaginalis, Neisseria gonorrhoeae, Candida 
albicans, Staphylococcus aureus, group B Streptococcus (GBS), Pseudomonas 
aeruginosa, Streptococcus agalactiae, Escherichia coli, and Prevotella bivia.  
Lactobacilli species have a higher affinity for vaginal host cell receptors and are able to 
displace these non-native pathogens before they can alter the vaginal microbiome.  In 
some instances, Lactobacilli species co-aggregate with non-native pathogens, allowing 
for easier clearance of invading pathogens (Huang, 2014).   
Although the presence and dominance of the Lactobacilli species are considered 
the hallmark of a healthy vaginal microbiome, there are women who are both 
asymptomatic and healthy overall who have a lower percentage of Lactobacilli species 
present within their vaginal microbiota.  It is believed that along with the healthy bacteria 
present in the vagina, the cycling of hormones during the menstrual cycle causes 
glycogen release by the vaginal epithelial cells that are turned over after release.  Bacteria 
attached to these epithelial cells are turned over as well, allowing for constant turnover of 
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cells and bacteria within the vagina, keeping some of the non-native bacteria from 
colonizing.  So although Lactobacilli species are largely responsible for vaginal 
microbiome health, there are other mechanisms that help to keep the vagina healthy 
(Huang, 2014).   
In women who lack the larger numbers of Lactobacilli species usually seen in 
healthy vaginal microbiomes, a larger and more diverse variety of other microbes are 
seen instead, including anaerobic or facultative bacteria from the genera Atopobium, 
Corynebacterium, Anaerococcus, Peptoniphilus, Prevotella, Mobiluncus, 
Gardnerella, and Sneathia.  These bacteria are associated with elevated pH levels and 
often a diseased state, but in the presence of an otherwise healthy vaginal microbiome, it 
is believed that these bacteria can contribute to either health or disease depending on 
other conditions within the microbiome.  Perhaps the joint presence of some of these 
species enables them to serve as commensal bacteria contributing to vaginal microbiome 
health (Huang, 2014).     
The composition of vaginal microbiota differs between women of different ethnic 
groups.  Specifically, the amount of Lactobacilli species present varies depending on 
ethnicity.  Women who are Asian or Caucasian typically have a larger proportion of 
Lactobacilli species than Black or Hispanic women.  Roughly 80-90% of the vaginal 
microbial communities in Asian and Caucasian women are dominated by Lactobacilli 
species.  This proportion is roughly 60% in women who identify as Black or Hispanic 
(Huang, 2014).  This could be due to genetic or environmental factors or a combination 
as the direct cause is unknown.  Environmental factors include personal habits such as 
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vaginal douching that more Black women report doing (47% vs. 17% in Caucasian 
women and 12.5% in Mexican American women; Arbour, 2009), although these do not 
completely explain  the the findings in Hispanic women (Gupta, 2019). In women who 
are Black or Hispanic, CST-IV is more common (~40%), and the pH of the vagina is 
higher than that observed in both Asian and Caucasian women (Ravel, 2011).  
 
The Vaginal Microbiota Across the Reproductive Lifespan 
The composition of the vaginal microbiome is largely dependent on age and life 
stage.  Early in childhood, the vaginal microbiome is quite different in its composition 
compared to what is observed during reproductive age.  Infants up to 6 weeks have 
vaginal microbiomes with an acidic pH that includes the common Lactobacilli species 
along with Streptococci, Enterobacteriaceae, S. epidermidis, and Enterococci.  After 6 
weeks of age until puberty, the vaginal microbiome has a neutral pH where Lactobacilli 
species are largely absent, and other species present during infancy are present along with 
Ureaplasma, Gardnerella, and Mycoplasma.  After reaching puberty, the vagina 
microbiome acquires an acidic pH and includes all prepubertal microbiota in addition to 
Lactobacilli species (Gupta, 2019).   
The microflora present upon entering puberty is especially important because the 
bacteria present in the vaginal microbiomes of women of reproductive age impact the 
health of the pregnancy.  Research has shown that the composition of microbes 
throughout the reproductive tract is important in pregnancy.  Women of reproductive age 
have higher estrogen levels than in other life stages.  This elevation in estrogen increases 
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the amount of glycogen stored in the vaginal walls.  Glycogen is the main food source for 
Lactobacilli species, which explains the abundance of these microbes present during 
puberty.  Newborn infants have microbiomes largely resembling that of their mothers due 
to persistence of maternal hormones, specifically estrogen (Gupta, 2019).   There have 
been some studies showing that infants born vaginally have early microbiota 
communities on the skin, in the gut, and in the oral and nasopharyngeal passages that 
have similar characteristics to their mother’s vaginal microbiome.  Babies delivered via 
cesarean section have microbiomes most closely resembling the microorganisms found 
on their mother’s skin.  It has also been observed that the mother’s intestinal bacteria 
influences the fetus’s intestinal microbiome communities in vitro as they often closely 
resemble each other (Huang, 2014).   
Lactobacilli species are present in the highest numbers between puberty and 
menopause, when estrogen levels are relatively high (Gupta, 2019).  Postmenopausal 
women have a vaginal microbiome showing a decline in Lactobacilli species.  The 
change in CST is due to low estrogen levels in postmenopausal women that affects the 
epithelial proliferation and maturation within the vagina.  With thinning of the vaginal 
epithelium in menopause, there is less accumulation of glycogen in the vagina and less 
nutrition available for Lactobacilli species (Smith, 2017).   
Many women who are postmenopausal experience various unpleasant symptoms 
that are hallmarks of menopause including insomnia, vaginal dryness, and hot flushes.  
Between 25-50% of postmenopausal women will experience vulvovaginal atrophy 
(VVA) due to a decrease in estrogen levels.  Symptoms of VVA include pain during 
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intercourse, bleeding post intercourse, burning sensation when urinating, vaginal itching 
and soreness, and foul-smelling discharge.  With the decrease in estrogen and 
subsequently glycogen, the vaginal microbiota of postmenopausal women will attract 
harmful microbes as the intravaginal pH increases.  Specifically, increases in Escherichia 
coli, Candida, Enterobacter, and Gardnerella are seen.  Some postmenopausal women 
benefit from topical estrogen treatments that can help alleviate some of the symptoms of 
VAA; women with contraindications for estrogen therapy may use vaginal lubricants for 
relief.  Both lubricants and estrogen therapy have side effects; new non-hormonal options 
are needed (Gupta, 2019).   
 
 
Figure 3: Microbial Composition of the Vaginal Microbiome During Different 
Stages of Life.  Upon reaching puberty, reproductive aged women have the largest 
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presence of Lactobacilli, with a similar Lactobacilli composition seen in infants, while 
these species are largely absent from pre-puberty and menopausal women (Gupta, 2019).  
 
Disruptions to the normal vaginal microbiome can happen daily.  Behavioral 
habits such as dietary choices, exercise frequency, and prevalence of sexual activities can 
change the vaginal microbiome, along with the use of hormonal contraceptives and 
lubricants.  Menstruation, hygiene practices, and the use of antibiotics may also affect the 
vaginal environment.  Douching or intravaginal cleansing, especially after sex or 
menstruation, eliminates much of the healthy, protective bacteria from the vagina, 
making this habit a risk factor for increased frequency of vaginal infections.  With 
antibiotics, prolonged use can lead to unwanted anaerobes becoming more numerous and 
active, leading to BV and increased susceptibility to STIs and urinary tract infections 
(UTIs) (Gupta, 2019).  Exposure to spermicides has also been shown to decrease the 
prevalence of Lactobacilli species, increasing the susceptibility of the user to vaginal 
infections (Huang, 2014).   
Other habits such as smoking and drinking can also affect the relationship 
between vaginal microbes and disease.  Smoking is known to decrease two of the 
Lactobacilli species commonly found in the vagina, L. crispatus and L. iners. Smokers 
are more prone to developing BV as well as STIs.  Stress, obesity, vitamin D deficiency, 
diabetes, and climate are additional factors that can harm the disease state of the vagina 
due to their negative effects on the beneficial bacteria within its microbiome (Huang, 
2014). 
The genetic factors that affect the vaginal microbiome are not completely 
understood, but some genetic variants have been linked to alteration of the vaginal 
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microbiome.  Innate immunity is especially important in the urogenital tract for fighting 
off foreign invaders.  Various innate immune responses are triggered when toll-like 
receptors (TLRs) interact with pathogen-associated molecular patterns (PAMPs).  Many 
of the responses involve inflammatory cytokines including interleukins (IL) 4 and 10.  
Single nucleotide polymorphisms (SNPs) in IL-4 and IL-10 have been linked to abnormal 
responses to the bacteria that cause BV in relation to preterm births. Additionally, similar 
abnormal responses have been seen with polymorphisms in TLR4 and Tumor necrosis 
factor (TNF)-α, also part of the innate immune response within the vaginal microbiome 
(Huang, 2014).   
 
The Vaginal Microbiome and STIs 
 Recent data suggests that the common STIs are more prevalent in certain women 
because of factors making the transmission of bacteria and viruses easier (Wessels, 
2018).  Certain behaviors as well as genetic and environmental factors may increase the 
likelihood of contracting an STI by decreasing healthy bacteria and increasing  
pathogenic microbes within the vagina.  Healthy bacteria are the Lactobacilli species, and 
a decrease in their presence signals an increase in anaerobes that are correlated with a 
higher risk of bacterial vaginosis, preterm births, and STIs. In particular, vaginal 
dysbiosis has been linked to an increased risk of acquiring chlamydia, gonorrhea, 
Trichomonas, HSV, HPV, and HIV (Torcia, 2019).  The microbiome profile lacking 
Lactobacilli is especially susceptible to contracting disease because of the increase in 
 
27 
inflammatory cytokines that can cause epithelial disruption and recruitment of cells to the 
areas targeted by the bacteria and viruses (Liu, 2019).   
 Bacterial vaginosis (BV) is the most common genital tract infection seen in 
women who are of reproductive age.  It is not an STI but increases the likelihood that the 
woman will contract an STI.  Typically, BV is characterized by a loss of Lactobacilli, 
causing the vaginal pH to increase to about 4.5.  Symptoms include a foul-smelling 
discharge, irritation, and a fishy odor (Torcia, 2019).  Microbes associated with BV vary, 
but infections usually result from the abundance of multiple anaerobic microorganisms.  
Along with increasing susceptibility to STIs, BV also increases the risk of preterm 
delivery in pregnant women.  Treating BV in asymptomatic pregnant women, however, 
does not decrease the risk of preterm delivery, possibly due to effects of antibiotic 
treatment (Nygren, 2008).  BV may be treated with the antibiotics metronidazole and 
single-dose secnidazole (Kaambo, 2018).   The recurrence rates for BV are high. For BV 
infections that repeatedly recur, treating with first-line antibiotics, using estrogen-
containing contraceptive methods, and ensuring male partners are circumcised can all 
help (Van de Wijgert, 2017).   
 Chlamydia trachomatis, the bacteria responsible for causing chlamydia infection, 
is able to more easily infect women with weakened reproductive tract barriers.  Many of 
these protective barriers are made up of Lactobacilli species, so when other species of 
bacteria dominate the microbiome, Chlamydia trachomatis takes advantage.  After 
invading the host, Chlamydia trachomatis triggers the production of IL-12, an 
inflammatory cytokine that stimulates the production of other cytokines as well as the 
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recruitment of inflammatory cells to the site of infection.  Chlamydia trachomatis needs 
the amino acid tryptophan to survive, so within the immune response to the invading 
bacteria, enzymes are also produced that eliminate free and available tryptophan.  
Unfortunately, microbiome environments lacking Lactobacilli dominance often have 
plentiful amounts of Prevotella, a bacterium that makes tryptophan.  Prevotella is also 
implicated in causing BV infections.  Although the immune system can activate to 
combat a chlamydial infection, the dysregulated microbiota not only creates an easier 
entry for Chlamydia, but can also support its growth by supplying needed tryptophan 
(Molenaar, 2018).   
 Another bacterial STI, gonorrhea, also has an increased prevalence of infection 
among women with vaginal microbiomes including lower levels of Lactobacilli and with 
subsequently higher pH levels.  Neisseria gonorrhoeae usually enters the body through 
the particularly vulnerable columnar cells of the endocervical glands. The main site of 
infection for this STI is the cervix.   When trying to prevent N. gonorrhoeae from 
entering the body, the presence of Lactobacilli species is the best defense.  In particular, 
the metabolites of Lactobacilli, hydrogen peroxide and lactic acid, are crucial in 
preventing infection.  The pH of the vagina is closely linked to gonorrhea risk (Zeng, 
2019).    
 Trichomoniasis, an STI caused by T. vaginalis, is more prevalent with vaginal 
microbiomes that are CST-IV dominant.  Whether the CST-IV was initially present and 
led to an increased rate of infection, or whether the T. vaginalis caused the switch to a 
CST-IV-dominant vaginal microbiome needs to be further studied.  T. vaginalis is known 
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to use the lactic acid produced by Lactobacilli to help itself adhere to the vaginal 
epithelium and gain entrance to the host.  After infection, the parasite modifies the 
vaginal microbiome via phagocytosis of the Lactobacilli species as well as by 
challenging the host mechanisms that protect the vaginal environment.  A higher pH 
caters to growth and proliferation of T. vaginalis after it has entered the host (Kalia, 
2020).   
 The acquisition of Human Papillomavirus (HPV) has also been linked to vaginal 
dysbiosis.  It has been shown that women who are HPV-positive often have either CST-
III dominant (L. iners-dominated) or a low presence of Lactobacilli species (CST-IV) in 
their vaginal microbiomes.  Women who have CST-II dominant microbiomes have the 
ability to clear HPV with more success than women who have other CST profiles.  
Women who are HPV positive also have microbiomes containing lower levels of 
glutathione metabolites.  The presence of lower concentrations of both reduced and 
oxidized metabolites of glutathione could indicate increased oxidative stress that lead to 
damage and death of various organelles within the cell (Borgogna, 2019). 
 Past studies have established an association between a decrease in Lactobacilli 
species and recurrent BV infections with herpes simplex virus type 2 infection.  
Simultaneous infection by BV and HSV causes increased shedding of herpes.   After 
becoming infected with HSV, additional vaginal dysbiosis occurs due to several 
hallmarks of HSV infection.  HSV has active and dormant periods.  When HSV is 
reactivated, the immune system is activated within the vaginal environment, causing 
additional changes to the microbiome that favor an increase in bacteria and pathogens 
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commonly associated with higher STI prevalence.  HSV reactivation also causes more 
iron to become available.  The increase in iron availability supports increased growth of 
Gardnerella vaginalis, a bacterium often seen in higher abundance in BV (Torcia, 2019).     
When the vagina is in a dysbiotic state, it can affect the T cells involved in the 
adaptive immune response.  Much of this suppression is due to IL-33, secreted in 
response to the dysbiosis and epithelial damage, that inhibits T cells by interfering with 
cytokines that recruit them to the site of infection. With a suppressed T-cell response, it 
becomes harder for the host to clear HSV, making the likelihood of the host contracting 
other STIs such as HIV greater.  When HSV is reactivated, it also increases the likelihood 
of acquiring HIV because the reactivated HSV disrupts the barrier of the vaginal 
epithelium and recruits cluster of differentiation (CD) cells to the site of disruption.  HIV 
can target CD4+ lymphocytes at the site of the HSV lesion.  Additionally, proteins 
involved in the regulation of HSV have been implicated in upregulating HIV (Torcia, 
2019).   
Women who are infected with HIV have been shown to have a higher proportion 
of CST-IV vaginal microbiomes.  Compared to CST-I, women who have microbiomes 
dominated by CST-IV have a four-fold greater likelihood of acquiring HIV.  On the 
molecular level, there are several mechanisms that could link vaginal dysbiosis and 
increased HIV incidence in women.  Firstly, when Lactobacilli species decrease in 
abundance, specifically L. crispatus, there is an accompanying decrease in availability of 
their metabolic product, D-lactate, which helps trap viruses by facilitating the reaction 
between mucins and HIV viral surface proteins (Torcia, 2019).  Additionally, an increase 
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in CST-IV increases the concentrations of enzymes available to degrade mucin, so there 
is less mucin to bind foreign particles.  Lastly, antigen-presenting cells (APCs), likely 
upregulated by bacteria present in CST-IV, produce cytokines that recruit CD4+ 
lymphocytes to the vaginal epithelium (Torica, 2019).  
Inflammatory responses are important and necessary in combating disease, but in 
the case of HIV, which targets the mucosal layer of the genital tract, women who are 
experiencing an inflammatory response are more likely to contract the virus (Noël-
Romas, 2020).  Pre-exposure prophylaxis (PrEP), antiviral medication taken by 
individuals at high risk of contracting HIV, is very effective in preventing HIV 
transmission via sex or injection drug use.  However, it has been shown that the efficacy 
of PrEP in preventing sexual transmission of HIV is greatly reduced in women who have 
a lower presence of Lactobacilli in their vagina (Velloza, 2017).   
Untreated HIV-positive women usually have an increased amount of anaerobes 
that cause vaginal inflammation, a larger HIV viral load in the genitals, and more 
shedding of the virus.  These women, who have uncontrolled HIV infection, have a 
higher likelihood of transmitting HIV to sexual partners (Liu, 2019).  For women who 
have undergone treatment for their HIV using antiretroviral therapy (ART), it has been 
shown that certain microbiome community types are correlated with lower concentrations 
of ART because the diversity of the vaginal microbiome, which affects the pH of the 
vagina, can determine how drugs treating the HIV can disperse into the vagina.  Certain 
drugs chosen to treat HIV-positive women such as Tenofovir® and Atazanavir® show 
the highest drug concentration ratio, vagina:plasma, when the vaginal microbiome 
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exhibits intermediate diversity as compared to either high vaginal species diversity or low 
vaginal species diversity.  The authors of this study, who found very different taxa 
dominating the low and high diversity microbiomes, hypothesized that the presence of 
different strains of bacteria could be changing the uptake or degradation of the type of 
ART being used (Donahue Carlson, 2017).   
 
The Effect of LARCs on the Vaginal Microbiome 
There is evidence both for and against the concept that certain contraceptive 
methods modify the vaginal microbiome.  As previously discussed, the composition of 
the microbiome impacts the susceptibility to certain STIs, so if contraceptives alter the 
microbiome, it may mean that the contraceptive user is at higher risk for contracting 
certain STIs.   
In one study looking at DMPA usage in Hispanic W hite and Black women, the 
vaginal microbiome at baseline was compared to samples taken at 1-month and 3-month 
timepoints.  When examining the data as one large group, no significant changes in the 
vaginal microbiome were apparent three months after beginning DMPA contraceptive 
use.  However, when analyzing the Hispanic White women and the Black women as 
separate groups, DMPA use in the Black women was associated with an increased 
diversity of vaginosis-associated bacteria (VNAB) and Prevotella species within their 
vaginal microbiomes.  The Hispanic White participants did not see an enrichment of 
VNAB upon beginning DMPA contraception or at 3-months post DMPA start.  
Differences in the Black women’s vaginal microbiome makeup, were noted when 
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comparing the baseline data to the 3-month post DMPA usage data.  In summary, DMPA 
usage did appear to alter the vaginal microbiomes of Black women after 3 months or 
more of usage (Yang, 2019).   
In previous studies, there was evidence that linked DMPA usage to an increased 
risk of HIV transmission.  Women with a predominance of Lactobacilli species in their 
vaginal microbiomes who using DMPA were three times more likely to contract HIV 
than women who were Lactobacilli dominant but using NET-EN or COC as 
contraceptives.  This difference in HIV acquisition was not seen in women who did not 
have Lactobacilli-dominant microbiomes. (Polis, 2016).  A similar study examining only 
DMPA usage and its risk of STI acquisition  among teenage women found that there was 
no significant correlation between 3 months of DMPA usage  and the incidence of STIs 
such as gonorrhea, trichomoniasis, and chlamydia.  A higher risk of STIs was only seen 
in participants who had a greater number of sexual partners during the study (Romer, 
2013).   
In a study using a mouse model for HSV-2 infection, DMPA and LNG usage 
were compared in relation to the susceptibility of treated mice to genital herpes infection.   
Both hormonal contraceptives reduced the expression of desmosomal cadherin 
desmoglein-1α (DSG1α).  Additionally, both DMPA and LNG appeared to increase the 
number of inflammatory cells present in the genital tissue region by allowing these cells 
to more easily pass through the more permeable mucosal epithelium.  When examining 
the effects of the contraceptives on untreated mice, it was found that DMPA increased the 
likelihood of vaginal infection by certain microorganisms by promoting increased 
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permeability and inflammation.  When uninfected mice were treated with DMPA and an 
additional estrogen delivered intravaginally, the mice were protected from HSV-2 
infections. Breakdown of the mucosal barrier, the first line of defense against pathogens 
in the vaginal microbiome, should be considered when starting a hormonal contraceptive 
regimen (Quispe Calla, 2016).   
Another study compared the effects of three different contraceptive methods, 
combined hormonal pills, DMPA, and LNG-IUD on the vaginal microbiome.  The study 
looked at 682 women who reported using either condoms, combined contraceptive pills, 
DMPA, or LNG-IUD.  The women included in the study reported only using one type of 
birth control method at the time they were enrolled in the study, and all participants were 
on their choice of birth control for at least 1 month.  The results indicated that women 
using combined hormonal pills had much higher levels of Lactobacilli species and less 
BV-associated bacterial species than women who used condoms.  DMPA users were 
more likely to have vaginal microbiomes that were Lactobacilli dominant than condom 
users.  DMPA users had fewer BV infections, but some of these users had higher levels 
of BV-associated species (A. vaginae and P. bivia) present in their vaginal microbiomes, 
while other users had lower levels of BV-associated species (G. vaginalis) present in their 
vaginal microbiomes.  In the LNG-IUD group, the amount of BV-associated species in 
the vaginal environment were much higher  than that of women who used combined 
hormonal pills (Brooks, 2017).   
One study only examined the effect of LNG-IUD use on the vaginal microbiome.  
This study involved only Caucasian women and compared the vaginal microbiome 1 
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week before method initiation through 12 weeks of LNG-IUD use.  None of the women 
had a recent history of pregnancy or hormone use.  The sample size of 11 women was 
small, but over 400 samples were collected.  Of the Lactobacilli species, L. crispatus was 
the most prevalent species in the vaginal microbiome, representing 48.9% of the total 
bacteria present.  In longitudinal samples from the same participant, the vaginal 
microbiome did not change significantly over 12 weeks of LNG IUD use (Jacobson, 
2014).   
In a study focused on the effects of DMPA, copper IUD, and LNG implant usage 
on STI risk, 7,829 women from South Africa aged 16-35 years old were included. They 
examined prevalence of chlamydia and gonorrhea after use of certain contraceptives as 
risk factors for HIV acquisition.  At the start, 18% of the women had chlamydia and 5% 
had gonorrhea.  After 18 months, the prevalence of chlamydia did not differ between the 
women on DMPA or using the copper IUD, or between the women using the copper IUD 
or LNG implant.  However, the risk of chlamydia was lower in those using DMPA than 
in those using the LNG implant (14% compared to 17%).  When examining gonorrhea 
prevalence after 18 months, 4% of DMPA users, 6% of copper IUD users, and 5% of 
LNG implant users were infected.  The prevalence of gonorrhea in the women using 
copper IUDs was significantly higher than that of women using DMPA (Deese, 2020).   
Another study compared the usage of a copper IUD and a LNG-IUD.  This study 
included 76 women, and data was collected at baseline (prior to contraceptive use) and at 
6 months after the start of contraceptive use.  A third sample was collected 12 months 
after initiation of contraception for 69 of the participants.  Participants had one of three 
 
36 
characteristic microbiome types:  a mixed Lactobacilli species dominant environment, an 
L. iners dominant environment, or an L. crispatus dominant environment.  Although 
some changes were observed from the start of the study through 12 months after 
contraception initiation, the dominant vaginal species at a given time was not associated 
with either copper IUD or LNG-IUD usage (Bassis, 2017).   
One study that examined various hormonal contraceptives and a copper IUD did 
not see any changes in the vaginal microbiomes of study participants at 1 month, 3 
months, or 6 months post contraception initiation.  The authors did find that usage of a 
copper IUD was correlated with an increase in BV diagnosis at 1, 3, and 6 months post 
contraception initiation.  In participants using the copper IUD, the amount of Lactobacilli 
species did not decline, but the prevalence of bacterial species often implicated in BV 
increased, including G. vaginalis and A vaginae. Although there are multiple factors that 
can contribute to vaginal microbiome changes, the women in this study utilizing copper 
IUDs were having less sexual intercourse than their counterparts, so their increased 
incidence of BV was likely not linked to more sexual intercourse (Achilles, 2018).   
In an additional study examining the effects of copper IUDs and LNG-IUDs on 
cervicovaginal cytokines, 20 women were enrolled who were STI-free.  Data was 
collected before insertion of the IUD and 4 weeks post IUD insertion.  Various cytokines 
were included in the analysis.  Levels of IL-α, IL- β, IL-6, and TNFα were increased and 
the chemokine MCP-1 was also increased four weeks post IUD insertion.  The cytokines 
that increased are pro-inflammatory cytokines that increase inflammation at the sites they 
act on, which may or may not increase the risk of STIs.  Although an increase in pro-
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inflammatory cytokines was seen with both IUDs, the copper IUD caused a more 




SPECIFIC AIMS  
 
Perturbations in the normal vaginal microbiota, or community of microorganisms 
inhabiting the vaginal body niche, are thus known to affect the risk of transmission of 
STIs. Vaginal microflora regulate the innate immunity of the epithelium that contributes 
to barrier function against infections. Studies have shown altered vaginal microbiota with 
DMPA injection, and conflicting studies support both altered and preserved vaginal 
microbiota with the LNG IUD. Few studies have compared several progestin LARC 
methods head-to-head or used culture-independent sequencing methodology.  
We proposed a prospective pilot study to evaluate the impact of different long-
acting progestin contraceptive formulations on the vaginal microbiome. Women who 
were planning to initiate DMPA, LNG IUD, and ESI contraception as well as controls 
seeking sterilization were recruited for the study from Boston Medical Center (BMC) and 
Women and Infants Hospital of Rhode Island (WIHRI), tertiary care centers with racially 
and socioeconomically diverse patient populations. Women had longitudinal follow-up 
with self-sampling of the vagina for sexually transmitted infection testing and 
metagenomics analysis at method initiation, 2-3 months, and 6 months.  
We identified and compared metagenomics profiles associated with DMPA, LNG 
IUD, and ESI contraceptive use by community analysis of vaginal swab samples from 
women collected longitudinally after contraceptive method initiation. We hypothesized 
that DMPA would increase community diversity in the vaginal microbiota, whereas the 
LNG IUD and ESI would not affect the balance of microorganisms in the vagina.   
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This study was innovative because of its prospective and longitudinal profiling of 
vaginal microbiota in women initiating long-acting progestin hormonal contraception, 
direct comparison between three highly effective contraceptive methods, the leveraging 
of cutting-edge sequence technologies to characterize complex communities and 
computational tools to aid in handling “big data,” and the racially and socioeconomically 
diverse patient cohort at BMC. Establishing the safest long-acting progestin contraceptive 
alternative will promote effective contraception use and lower rates of STI acquisition 





 Women between the ages of 18-40 initiating long-acting progestin contraception 
or who were seeking tubal sterilization were enrolled at a routine office visit at the BMC 
or WIHRI Ob/Gyn ambulatory practice/family planning clinics.  Exclusion criteria 
included women who were non-English speaking, had used hormonal contraception 
within the past 3 months (barrier contraception use including condoms or diaphragm 
were acceptable and to be recorded), were currently menstruating, had had vaginal 
intercourse within 48 hours of the visit, had known or suspected pregnancy within the 
past 6 weeks, were using the LARC for a primary indication other than contraception 
(e.g. pelvic pain, menorrhagia), had a current STI or vaginitis (yeast or BV), use tampons, 
douche regularly, had recent antibiotic use within the last 4 weeks, or were HIV positive 
or on immunosuppressive therapy (organ transplant, chemotherapy). 
 
Enrollment 
Enrollment took place over a period of 6 months to allow for longitudinal follow-
up and analyses. For this pilot study, we were seeking a total of 30 long-acting progestin 
contraceptive initiators with 10 subjects in each method group [Depo Provera (depot 
medroxyprogesterone acetate, DMPA), Mirena IUD (levonorgestrel intrauterine device, 
LNG IUD), or Nexplanon (etonogestrel subdermal implant, ESI)] and 6 age and race-
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matched control patients seeking tubal sterilization were selected for longitudinal STI 
screening and vaginal sampling for microbiome analysis. 
 During study recruitment, staff were alerted to potentially eligible patient.  After a 
subject gave consent to participate in the study, a brief interview was conducted to review 
recruitment criteria to confirm eligibility.  Informed consent was then obtained from the 
subject by study staff.   
A trained staff member administered a brief sociodemographic/habits 
questionnaire that included questions on age, race, body mass index, gravidity/parity, 
date of last menstrual period, smoking status, substance abuse (alcohol or drugs), history 
of STIs and most recent episode, history of vaginitis and most recent episode, weekly 
frequency of coitus, number of lifetime sexual partners, and prior contraceptive use. 
Some but not all of these questions would have been asked as part of standard clinical 
care for contraception initiation. 
Vaginal swabs for STI screening and microbiome analysis were collected from 
subjects. Subjects were instructed to self-sample the vagina, or to have the provider 
sample the vagina if not comfortable with self-sampling. Swabs were collected at three 
time points including method initiation, 2-3 months later, and 6 months later. Each visit 
involved sampling with one APTIMA swab for STI testing and two Dacron swabs (stored 
dry).  Swabs were then immediately stored at -20°C and then moved to -80°C for longer 
term storage.  At visits after the initial visit, subjects were asked about interval STIs or 
vaginitis.  At the second visit, a short questionnaire and the same swabs were collected; 
the participant was given a $25 gift card.  At the third visit, a short questionnaire and the 
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same swabs were collected; the participant was given a $50 gift card.  The first visit took 
place during the patient’s initial visit to initiate long-acting contraception or to discuss 
surgical sterilization and thus lasted 30-40 minutes. The second and third visits were 
briefer and lasted 15-20 minutes. 
 
Figure 4: Picture Guide to Patient Vaginal Self-Sampling. This guide was given to 
patients who wished to self-sample the vagina for each visit. 
 
Specific Experimental Interventions 
APTIMA vaginal swab specimens were assayed for Trichomonas vaginalis, 
Chlamydia trachomatis, and Neisseria gonorrhoeae using DNA amplification in the 
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clinical lab. Nugent scores and pH correlate strongly with certain microbiome profiles 
and thus did not need to be performed separately.  
Microbiome samples collected at each time point were analyzed and compared to 
the initiation sample to detect longitudinal differences.  Microbial species composition 
and abundance sampled with self-collected vaginal swabs have been shown to be 
equivalent to those from swabs collected by clinicians (Forney, 2010). However, if the 
patient was uncomfortable with self-sampling, the clinician would administer the swabs. 
Swabs were inserted so that the entire swab head was completely within the orifice, and 
then the swab was rotated 6 times or for 20 sec while in contact with the vaginal wall. 
Both swabs could be inserted at the same time. Swabs were delivered to the respective 
laboratories at BMC or WIHRI shortly after sampling and stored immediately at -80ºC 
prior to DNA extraction.  
In the laboratory, DNA was isolated from the vaginal swabs with QIAGEN 
DNeasy Blood &Tissue kits following the tissue spin-column protocol with minor 
modifications. Swabs were thawed on ice and vortexed vigorously for 5 min to resuspend 
cells before analysis.  Ultra-high-throughput data generation for microbial community 
profiling employed well-established protocols using the 16S ribosomal DNA (rDNA), 
515F and 806R universal primers, and sequencing on the Illumina MiSeq platform 
(Kozich, 2013).  Overlapping, paired-end read pairs were ‘stitched’ to generate error-
corrected sequences spanning the length of the amplicon.  
DNA extraction and sequencing of samples was performed by Dr. Doyle Ward at 
University of Massachusetts Medical Center. De novo and reference-based clustering of 
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sequences into operational taxonomic units (OTUs) was applied using a combination of 
UPARSE (Edgar, 2013) and QIIME (Bolyen, 2019) packages to generate sample-based 
OTU tables and classifications and corresponding phylogenetic trees for the sample 
sequences. Dr. Ward is experienced with all data production and processing activities 
described above. REDCap was used for data management because it is a standardized 
software system that supports rapid setup of secure, web-based study-specific database 
systems and associated forms. 
Data Analysis 
Use of the following two approaches provided preliminary data for future larger 
studies from this limited pilot study. If our hypothesis of a vaginal microbial shift with 
Depo Provera (DMPA) use was confirmed (our PRIMARY analysis), these tools would 
enable visualization of the differences. The tables of relative abundance of taxonomic 
groups were used to identify differential bacterial biomarkers present among patient and 
sample classes. Two bioinformatics tools particularly useful for biomarker discovery are 
linear discriminant analysis effect size (LefSe) (Segata, 2011) and multivariate 
association with linear models (MaAsLin) (Mallick, 2021).  LefSe used the non-
parametric factorial Kruskal-Wallis test to detect features with significant differential 
abundance with respect to class comparison of interest (e.g. control vs. DMPA use).  
Biological consistency was subsequently tested using pairwise tests among 
subclasses (e.g. smokers vs. nonsmokers) using the (unpaired) Wilcoxon rank-sum test. 
Linear Discriminant Analysis (LDA) with bootstrapping was used to rank differentially 
abundant features based on their effect sizes, which was an effective approach to detect 
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the microorganisms that most differentiate two microbial communities with respect to p 
values. Significance tests were performed at all clade levels for frequencies that differ 
significantly with respect to the different categories. A significance alpha of 0.05 and an 
effect size threshold of 2 was used for all biomarkers discussed in this study.  
MaAsLin is a multivariate statistical framework that finds associations between 
clinical metadata and microbial community abundance or function. The clinical metadata 
can be of any type: continuous (age and body mass index), Boolean (sex), or 
discrete/factor (cohort groupings and phenotypes). MaAsLin performs boosted, additive 
general linear models between one group of data (metadata – the predictors) and another 
group (in our case microbial abundance – the response). The boosting was used to select 
metadata that showed some potential to be associated with abundances. Selected 
metadata was used in a general linear model using metadata as predictors and OTU 
arcsin-square root transformed abundance as the response (to account for sparse data 
characteristic of metagenomic studies). 
Effects of different sources of variation (e.g. smoking status, presence of STI) on 
community structure was assessed in multivariant analysis of variance (MANOVA) 
models, and for OTUs of interest, analysis of variance (ANOVA). Analyses used either 
frequencies of OTUs or principal component analysis (PCA) values from major axes. 
Effects of various sources of variation on community diversity was analyzed by ANOVA 
on diversity indices, obtained from qualitative insights into microbial ecology (QIIME).  
To classify community samples based on sources of variation, discriminant 
analysis was used, with the likelihood that a community was assigned to a given class 
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being estimated using individual frequencies of OTUs as predictor variables. This method 
identified specific community samples as ‘typical’ or ‘atypical’ members of a given class 
and identified OTUs significantly affecting classification of community samples, thus 
associated with use of a particular contraceptive. Directed identifications at strain level 
across samples and their combinations in context of health and disease status was 
evaluated by t-tests, ANOVA, or appropriate non-parametric statistics. 
The Dirichlet-multinomial distribution allowed the analyst to perform tests of 
hypotheses (e.g., compare microbiomes across groups) and estimated parameters 
describing microbiome properties. The Dirichlet-multinomial distribution prevented Type 
I error inflation by accounting for the over-dispersion in count data in the microbiome. 
This model allowed comparison of microbiome populations between more than two 
groups of subjects (i.e. Mirena IUD users, DMPA users, Nexplanon implant users). This 







583 potential subjects were screened for the study, and 21 patients were enrolled. 
Of the twenty-one women enrolled, 1 initiated DMPA, 14 initiated LNG IUD, 6 initiated 
ESI, and there were no controls.   
 
Table 1: Demographics of the 21 subjects enrolled in the study. 
Demographic  No (%) 
Ethnicity  
     Non-Hispanic 18 (85.7) 
     Hispanic 3 (14.3) 
Race  
     White 5 (23.8) 
     Black/African American 10 (47.6) 
     Asian 2 (9.5) 
     Native American, Native 
Hawiian/Pacific Islander 
0 




Prior histories of each subject were taken before enrollment in the study.  History 
included information about types of contraception used prior to three months ago, any 




Table 2: Prior History of Contraceptive Use, Vaginitis, and STIs 
 
Demographic  No (%) 
Use of hormonal contraception PRIOR TO last 3 months 13 (61.9) 
     OCP 5 (26.3) 
     LNG IUD 5 (26.3) 
     DMPA       7 (36.8) 
     Condom 2 (10.5) 
     Patch 1 (5.3) 
     Other (withdrawal, pregnancy, postpartum, not sexually active since 
baby) 
5 (26.3) 
Prior history of vaginitis 5 (23.8) 
           Yeast vaginitis                3 (60) 
           Bacterial vaginosis 2 (40) 
Prior history of STI 4 (21.1) 
     Gonorrhea 2 (11.8) 
     Trichomonas 1 (5.9) 
     Other 1 (5.6) 
 
Population Characteristics 
After histories were taken, participants were asked how sexually active they were 
and how many sexual partners they have had in their lifetime (Table 3).   Data was 
collected on tobacco use, alcohol use, and substance use (Table 3).   
 
Table 3: Participant Drug, Alcohol, and Tobacco Use and Prior Sexual History 
Population Characteristics: Tobacco, Alcohol, and Drug Use  No (%) 
     Current smoker 0 
     Former smoker 3 (14.3) 
     Never smoker 18 (85.7) 
     Current alcohol use (median 1 drink per day) 3 (14.3) 
     Current drug use (marijuana)  1 (4.8) 
Population Characteristics: Sexual History Median 
     Number of vaginal intercourse episodes/week 2 




Data for Patient Follow-up Appointment #2 
 At the second appointment (3 months post initiation of contraception) patients 
were run through the initial exclusion criteria to better to determine which specific 
variables could be influencing the data collected at that time interval (Table 4).  At the 
second appointment, there were 10 swabs collected.  Of the 10 swabs collected, 7 of the 
women were on LNG IUD and 3 were on ESI.  None of the participants from the second 
appointment were using DMPA for contraception.  All STI testing was negative (Table 
4).  
Table 4: Demographics and STI Results from Visit 2.  Visit 2 was 3 months post-
contraception initiation.  At this visit swabs were collected from 10 subjects including 7 
in the LNG IUD group and 3 in the ESI group.  No data was collected from the DMPA 
group.   
 
Demographics No (%) 
     Vaginal intercourse <48hrs  1 (10) 
     Pregnancy, Douching, Tampon, Condom, Diaphragm  0 
     Antibiotic use since last visit 1 (10) 
          Axillary abscess, I&D, unknown abx 14d 
     Vaginitis, STI since last visit  0 
STI Results  No (%) 
     Chlamydia  0 
     Gonorrhea  0 
     Trichomonas  0 
 
 
Data for Patient Follow-up Appointment #3 
 At the third appointment (6 months post initiation of contraception) patients were 
run through the initial exclusion criteria to better to determine which specific variables 
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could be influencing the data collected at that time interval (Table 5).  At the third 
appointment, there were 8 swabs collected.  Of the 8 swabs collected, 3 of the women 
were on LNG IUD and 5 were on ESI.  None of the participants from the third 
appointment were using DMPA for contraception. All STI testing was negative (Table 5).  
 
Table 5: Demographics and STI Results from Visit 3.  Visit 3 was 6 months post-
contraception initiation.  At this visit swabs were collected from 8 subjects including 3 in 
the LNG IUD group and 5 in the ESI group.  No data was collected from the DMPA 
group.   
 
Demographics No (%) 
     Vaginal intercourse <48hrs  0 
     Pregnancy, Douching, Tampon, Condom, Diaphragm  0 
     Antibiotic use since last visit 0 
          Axillary abscess, I&D, unknown abx 0 
     Vaginitis, STI since last visit  0 
Results  No (%) 
     Chlamydia  0 
     Gonorrhea  0 
     Trichomonas  0 
 
 
Vaginal Microbiome of Women Who Are Postpartum Differs From Those Who Are 
Not Postpartum 
 
All baseline and subsequent STI testing was negative.  Additionally, there were 
no significant differences both by LefSe and MaAsLin between any of the LNG 
contraceptives (Mirena IUD, DMPA injection, and Nexplanon implant) used.  After 
analyzing the different contraceptive methods used, an analysis by race (Black vs. non-
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Black) was also done. No differences in the vaginal microbiota profiles were seen based 
on race, likely due to the small sample size of the study.   
The analysis then examined differences in vaginal microbiota between subjects 
who were either not postpartum (i.e. remote from pregnancy), 12 weeks or less 
postpartum, and more than 12 weeks postpartum.  To identify significant taxa between 
these three groups, data was evaluated using LefSe and MaAsLin.  Many of the analyses 
by MaAsLin did not find significant differences between the respective groups being 
analyzed while LefSe did. Because of this, LefSe figures only are included for simplicity.  
Significant MaAsLin data is summarized in Table 6.  The most significant differences 
seen by MaAsLin were between the women who were not postpartum and those who 
were more than 12 weeks postpartum (Table 6).  
The first analysis consisted of grouping all women who were postpartum together 
and examining differences between that group and all women who were not postpartum.  
For the postpartum group, the first sample was used from those 12 weeks or less 
postpartum and for the women who were not postpartum, and for the women who were 
12 weeks or more postpartum, the last sample was used.  This was done to maximize the 
number of subjects that could be included in the analysis.  Analysis by LefSe indicated 
that there was enrichment with the family Steptococcaeceae for women who were 
postpartum (Figure 5).  Analysis by MaAsLin indicated no significant differences 






Figure 5: Diversity of the Vaginal Microbiome Between Women Who Are 
Postpartum and Those Who Are Not Postpartum. The diversity between women who 
are postpartum and those who are not is shown by LefSe.  The cladogram indicates that 
there is enrichment of the family Streptococcaceae for women who are postpartum.   
 
 
 The second analysis examined differences between the two postpartum groups, 
women who were 12 weeks or less postpartum (early postpartum) and women who were 
more than 12 weeks postpartum (late postpartum).  For the 12 weeks or less postpartum 
group, the first sample was used from those 12 weeks or less postpartum and for the 
women who were 12 weeks or more postpartum, the last sample was used.  Analysis by 
both LefSe and MaAsLin indicated no significant differences in the vaginal microbiota of 





Figure 6: Diversity of the Vaginal Microbiome Between Women Who Are 12 Weeks 
or Less Postpartum and Women Who Are More Than 12 Weeks Postpartum. The 
diversity between women who are 12 weeks or less postpartum and those who are more 
than 12 weeks postpartum is shown by LefSe.  The cladogram indicates that there is no 
significant differences in the diversity of the vaginal microbiota between the two 
postpartum groups.   
 
Vaginal Microbiome of Women Who Are More Than 12 Weeks Postpartum Differs 
from Those Who Are Not Postpartum 
 
The third analysis looked at women who were more than 12 weeks postpartum 
and women who were not postpartum.  For both groups, the last sample collected was 
used.  Analysis by both LefSe and MaAsLin found significant differences between the 
two groups.  LefSe analysis indicated enrichment of 8 different taxa for the women who 
are more than 12 weeks postpartum, when compared to those women who are not 
postpartum (Figure 7).  For women who were not postpartum, their vaginal microbiota 
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profiles were enriched for families Actinomycetacea, Prevotellaceae, Lachnospiraceae, 
Desulfovibrionaceae, and Enterobacteriacea; orders Bacteroidales, Desulfovibrionaceae, 
and Enterobacteriales; and classes Bacteroidia and Deltaproteobacteria.  The LefSe 
analysis was enriched for the family Enterbacteriacea and the order Enterobacteriales 
when examining the vaginal microbiota of women who were more than 12 weeks 
postpartum.   
 
Figure 7: Diversity of the Vaginal Microbiome Between Women Who Are More 
Than 12 Weeks Postpartum and Women Who Are Not Postpartum. The diversity 
between women who are more than 12 weeks postpartum and women who are not 
postpartum is shown by LefSe.  The cladogram indicates that there are significant 
differences in the diversity of the vaginal microbiota between the two postpartum groups. 
Compared to women who were more than 12 weeks postpartum, the vaginal microbiota 
profiles of non-postpartum women were enriched for families Actinomycetacea, 
Prevotellaceae, Lachnospiraceae, Desulfovibrionaceae, and Enterobacteriacea; orders 
Bacteroidales, Desulfovibrionaceae, and Enterobacteriales; and classes Bacteroidia and 
Deltaproteobacteria.  The LefSe analysis indicated enrichment for the family 
Enterobacteriacea and the order Enterobacteriales for women who are more than 12 




The MaAsLin data indicated significance (q value < 0.05) for women not 
postpartum for 2 families, Aerococcaceae and Streptococcaceae (Table 6).  The same 
analysis indicated significance for women who were more than 12 weeks postpartum for 
3 families: Lachnospiraceae, Ruminococcaceae, and Erysipelotrichaceae (Table 6).    
 
Table 6: Diversity of the Vaginal Microbiome Between Women Who Are More 
Than 12 Weeks Postpartum and Women Who Are Not Postpartum.  The diversity 
between women who are more than 12 weeks postpartum and women who are not 
postpartum is summarized in a table after MaAsLin analysis.  The table indicates that 
there are significant differences in the vaginal microbiota between the two postpartum 
groups. The MaAsLin data indicated significance (qval < 0.05) for women not 
postpartum for 2 families, Aerococcaceae and Streptococcaceae (indicated in green), and 
for women more than 12 weeks postpartum for 3 families: Lachnospiraceae, 
Ruminococcaceae, and Erysipelotrichaceae (indicated in red).    
 
feature coef pval qval 
d_Bacteria/p_Firmicutes/c_Bacilli/o_La
ctobacillales/f_Aerococcaceae 
-0.10923822 0.0005803 0.04061969 
d_Bacteria/p_Firmicutes/c_Bacilli/o_La
ctobacillales/f_Streptococcaceae 
-0.16020773 0.0072972 0.13617228 
d_Bacteria/p_Firmicutes/c_Clostridia/o
_Clostridiales/Lachnospiraceae 
0.30010755 0.00910586 0.13617228 
d_Bacteria/p_Firmicutes/ c_Clostridia/ 
o_Clostridiales/f_Ruminococcaceae 




0.00571035 0.00657374 0.13617228 
 
Vaginal Microbiome of Women Who Are 12 Weeks or Less Postpartum Differs 
from Those Who Are Not Postpartum 
The fourth analysis compared women who were 12 weeks or less postpartum and 
women who were not postpartum.  For the 12 or less weeks postpartum group, the first 
sample was used, and for the women who were not postpartum the last sample was used.  
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Analysis by LefSe indicated that there was enrichment with the family Steptococcaeceae 
and within the class Gammaproteobacteria for women who were 12 weeks or less 
postpartum (Figure 8).  Analysis by MaAsLin indicated no significant differences 




Figure 8: Diversity of the Vaginal Microbiome Between Women Who Are 12 Weeks 
or Less Postpartum and Those Who Are Not Postpartum. The diversity between 
women who are 12 weeks or less postpartum and those who are not postpartum is shown 
by LefSe.  The cladogram indicates that there is enrichment of the family 
Streptococcaceae and the class Gammaproteobacteria for women who are 12 weeks or 




 In the vaginal microbiome, less diversity is more beneficial to health.  Individuals 
with more diverse species within their vaginal microbiomes have higher risks of infection 
(Smith, 2017).  Microbiome disruptions and changes may result from behavioral habits 
such as dietary choices, exercise frequencies, and hygiene practices (Gupta, 2019).  
Smoking, alcohol use, stress, obesity, vitamin D deficiency, diabetes, and climate are 
additional factors that may negatively affect the disease state of the vagina due to 
disruption of commensal bacteria within its microbiome (Huang, 2014).   
 Many previous studies, mostly in the context of increased risk of STIs, have 
examined the effects of different types of contraception on the vaginal microbiome.  The 
relationship between different contraceptives and the increased risk of STI infection due 
to disruption of the vaginal microbiome is not completely clear.  Head-to-head 
comparisons of the vaginal microbiome impact of long-acting progestin contraceptives, 
some of the most effective contraceptive options available, are lacking.  We hypothesized 
that DMPA would increase community diversity in the vaginal microbiota, whereas the 
LNG IUD and ESI would not affect the balance of microorganisms in the vagina.   
 We compared the vaginal metagenomic profiles of women initiating either 
DMPA, LNG IUD, or ESI contraceptive use.  Vaginal swabs were collected prior to 
beginning contraception, 3 months post contraception initiation, and 6 months post 
contraception initiation.  DNA was extracted, and 16S rDNA gene sequencing was 
performed to characterize vaginal microbiome composition. LefSe and MaAsLin were 
used in our statistical data analyses.  We found no differences over time in the vaginal 
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microbiota of the women who initiated each type of contraceptive.  We also found no link 
between contraceptive use and STIs as baseline tests and subsequent analysis for 
chlamydia and gonorrhea were all negative.  Because we found no link between vaginal 
microbiome profiles and type of progestin contraceptive being used, we also looked at 
other variables including race and postpartum status.  When looking at race, we found no 
clear patterns between Black women and nonBlack women in terms of their microbiomes 
at each time point.  This was likely due to low sample size in the study.    
 On examining the microbiomes of women who were recently postpartum (less 
than 12 weeks), late postpartum (over 12 weeks postpartum), or who were remote from 
pregnancy, there were some differences in the metagenomic profiles.   When grouping all 
postpartum women together, regardless of how recently they had given birth, and 
comparing them to women who were remote from pregnancy, analysis by LefSe 
indicated that there was enrichment with the family Steptococcaeceae for women who 
were postpartum.   
 When comparing women who were more than 12 weeks postpartum to those who 
were not postpartum, LefSe analysis indicated enrichment of 8 different taxa for women 
who were not postpartum including the families Actinomycetacea, Prevotellaceae, 
Lachnospiraceae, Desulfovibrionaceae, and Enterobacteriacea; orders Bacteroidales, 
Desulfovibrionaceae, and Enterobacteriales; and classes Bacteroidia and 
Deltaproteobacteria.  The LefSe analysis was enriched for the family Enterobacteriacea 
and the order Enterobacteriales when examining the vaginal microbiota of women who 
were more than 12 weeks postpartum.  The MaAsLin data indicated significance (qval < 
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0.05) for women not postpartum for 2 families, Aerococcaceae and Streptococcaceae.  
The same analysis indicated significance for women who were more than 12 weeks 
postpartum for 3 families Lachnospiraceae, Ruminococcaceae, and Erysipelotrichaceae.  
 When comparing the women who were 12 weeks or less  postpartum to women 
who were not postpartum, analysis by LefSe indicated that there was enrichment with the 
family Steptococcaeceae and within the class Gammaproteobacteria for women who 
were 12 weeks or less postpartum.   
 Pregnancy does appear to alter the vaginal microbiome.  One study that examined 
the vaginal microbiome throughout pregnancy and postpartum found that the composition 
of the microbiome after pregnancy shifts from favoring Lactobacilli species to increased 
alpha diversity.  This was the trend regardless of race or ethnicity.  The study did note 
some differences with race in the vaginal microbiome profiles of pregnant women.  They 
found that amongst the British population in their study, there was a predominance of L. 
jensenii amongst Caucasian and Asian women.  In the samples from Black women, they 
observed the absence of L. gasseri in many of the samples (MacIntyre, 2015).  This 
general trend of less Lactobacilli species present in the vaginal microbiomes of Black 
women compared to their Asian and Caucasian counterparts is something that has been 
observed in multiple studies (Huang, 2014).   
 Several other studies have confirmed that the pregnant vaginal microbiome is less 
diverse than that of women who are not pregnant.  The less diverse pregnant vagina does 
appear to be more Lactobacilli-dominant when compared to women who are not 
pregnant.  Studying the vaginal microbiome during pregnancy and just after giving birth 
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is important because it may shed light on the genesis of obstetrical complications.  It is 
believed that the vaginal microbiome and the species that dominate it during pregnancy 
may contribute to preterm labor and adverse pregnancy outcomes (Gupta, 2020).   
 Other studies have found that the decrease in Lactobacilli species and the increase 
in diversity of various species in the postpartum vagina is likely due to falling estrogen 
levels post pregnancy.  Researchers have found that the postpartum vagina begins to 
mimic the gut microbiome with its diversity, likely due to the possible translocation of 
stool microbiota to the vagina.  This relationship needs to be explored further.  
Regardless, a very diverse and less stable vaginal microbiome postpartum is significant 
because this may impact STI and future obstetrical risks (Gupta, 2020).   
 In another study examining a subset of women in the US, the vagina was found to 
be more diverse postpartum, with lower amounts of Lactobacilli species and increased 
levels of Streptococcus anginosus and Prevotella bivia.  Postpartum vaginal secretions 
also appeared to differ from pre-pregnancy and pregnancy secretions, with much 
decreased levels of lactic acid and increased amounts of HSP70 and hyaluronan (Nunn, 
2021), indicating the presence of a higher vaginal pH and inflammation.  A similar study 
examining the postpartum vaginal microbiomes of women in rural Malawi found a 
similar trend, with a decrease in Lactobacilli species and an increase in G. vaginalis.  As 
the time from pregnancy increased, the authors found an increase in Lactobacilli species, 
but G. vaginalis remained dominant in many of the women in the study up to a year 
postpartum (Doyle, 2018).   
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 Although more significance was seen when comparing the various postpartum 
groups to women remote from pregnancy with Lefse, the data that is most relevant are the 
differences seen with both Lefse and MaAsLin because q-values adjust for more 
confounding factors than p-values when examining and correcting for many taxonomic 
units.  The MaAsLin data found enrichment of three families, Lachnospiraceae, 
Ruminococcaceae, and Erysipelotrichaceae, in women who were more than 12 weeks 
postpartum.  Lachnospiraceae has been found to be strongly correlated with an increased 
susceptibility to BV infections (Hummelen, 2010), and Ruminococcaceae is not known to 
cause BV but has been seen in association with active BV infections (Hao, 2011).  BV is 
more prevalent in women with more diverse vaginal microbiomes, and postpartum 
vaginal microbiomes are more diverse than pregnant vaginal microbiomes.  This 
relationship between the dominant species present in the vaginas of postpartum women 
and their susceptibility to other infections should be further examined.     
 Study strengths included the successful collaboration between hospitals in two 
different states, the large number of subjects screened for the study in a short amount of 
time, and the use of a combined metagenomics approach to fully examine all variables 
and correlations in the data set.  Weaknesses include the exclusion criteria that made 
enrollment especially challenging because it was very strict, low sample numbers, and 
study subject loss to follow-up after enrollment.   
 Although we did not see any differences in vaginal microbiota in women using 
different types of long-acting progestin contraception, this is a positive outcome because 
changes in vaginal microbiota in response to contraception use would be undesirable.  
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We were able to see some differences in the vaginal microbiota of postpartum women 
and those who were not postpartum, but the effects of those differences remain unclear.  
Future studies should further probe the relationship between postpartum vaginal 
microbiomes and disease.  It would also be beneficial to follow women postpartum who 
are trying to conceive again to attempt to draw correlations between the recovering 
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